Nagilma (Metformin Hydrochloride, Linagliptin)

Metformin Hydrochloride and Linagliptin, the active ingredient in Nagilma, is a Biguanide / DPP‑4 inhibitor presented as an oral dosage form for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to control blood glucose levels. It is marketed in the European Union and is prescribed by healthcare professionals.

GNH USA supplies Nagilma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for importers.

Nagilma is an oral antidiabetic medication that targets hyperglycaemia in type 2 diabetes.

- Type 2 diabetes mellitus: improves overall glycaemic control when used with diet and exercise. - Inadequate control on metformin alone: provides additional glucose‑lowering effect as part of combination therapy. - Adults with renal impairment: linagliptin component can be used without dose adjustment, offering a convenient option for this subgroup.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea. - Upper respiratory symptoms: nasopharyngitis or mild cough. - Headache: transient and usually mild. - Skin reactions: mild rash or pruritus.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic complication. - Severe hypersensitivity: including angio‑edema or Stevens‑Johnson syndrome. - Pancreatitis: acute inflammation of the pancreas presenting with abdominal pain and elevated enzymes.

Before initiating therapy, consider the following precautions: - Renal function: assess creatinine clearance, especially in patients with chronic kidney disease. - Hepatic disease: monitor liver enzymes as metformin is contraindicated in severe hepatic impairment. - Cardiovascular status: use with caution in patients with unstable heart failure. - Concomitant medications: review for drugs that may increase risk of lactic acidosis or affect glucose control. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture and direct sunlight.

When prescribing Nagilma, be aware of potential drug interactions.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate lactic acidosis; discontinue metformin before and after imaging. - Strong CYP3A4 inhibitors: can increase linagliptin exposure.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of metformin. - Beta‑blockers: can mask hypoglycaemia symptoms. - Corticosteroids: may raise blood glucose, requiring dose adjustments.